Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication.
Physiological and pathophysiological aspects of systemic and cardiac haemodynamics are reviewed with appraisal of Carl J. Wiggers merits and contributions to the research and developments in this field and his early recognition of the significance of the flow properties of blood in impaired circulation. Pharmacological agents involved in treatment of peripheral vascular diseases are discussed with special regard to the haemorheologically active xanthine derivative pentoxifylline. The profile of pentoxifylline as it emerges from experimental pharmacological and clinical studies is presented paying special attention to the haemorheological properties of the drug. Pharmacokinetic features of pentoxifylline are surveyed touching absorption, blood levels, metabolism and excretion aspects. Basing on the available data pentoxifylline is regarded as a promising drug in the treatment of circulatory ischemic disorders, especially in intermittent claudication.
D000042:Absorption; D000721:Ancrod / Q000627:therapeutic use; D001809:Blood Viscosity / Q000187:drug effects; D011464:Epoprostenol / Q000627:therapeutic use; D004912:Erythrocytes / Q000187:drug effects; D006439:Hemodynamics; D049673:History, 20th Century; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D010431:Pentoxifylline / Q000378:metabolism / Q000627:therapeutic use* / Q000652:urine; D010974:Platelet Aggregation / Q000187:drug effects; D012212:Rheology / Q000266:history; D013805:Theobromine / Q000031:analogs & derivatives*
D011464:Epoprostenol; D000721:Ancrod; D013805:Theobromine; D010431:Pentoxifylline